Literature DB >> 31355513

Cardiologist as a cardiometabolic specialist.

Vasiliki Katsi1, Ioannis Andrikou1, Costas Tsioufis2, Dimitris Tousoulis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31355513      PMCID： PMC8030368          DOI： 10.1111/jch.13636

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  24 in total

Review 1.  Canagliflozin: a new hope in the antidiabetic armamentarium.

Authors:  Vasiliki K Katsi; Christos A Michalakeas; Charalambos E Grassos; Georgia D Vamvakou; John P Lekakis; Dimitris Tousoulis; Christodoulos I Stefanadis; Thomas K Makris; Ioannis E Kallikazaros
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2013-12

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 3.  Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.

Authors:  Thomas A Zelniker; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2018-07-31       Impact factor: 24.094

Review 4.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

5.  Changes in diabetes-related complications in the United States, 1990-2010.

Authors:  Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

6.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

Review 7.  SGLT2 Inhibitors and Mechanisms of Hypertension.

Authors:  Alexandros Briasoulis; Omar Al Dhaybi; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2018-01-19       Impact factor: 2.931

8.  Cardiologist as a cardiometabolic specialist.

Authors:  Vasiliki Katsi; Ioannis Andrikou; Costas Tsioufis; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-29       Impact factor: 3.738

9.  Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe.

Authors:  Mika Kivimäki; Eeva Kuosma; Jane E Ferrie; Ritva Luukkonen; Solja T Nyberg; Lars Alfredsson; G David Batty; Eric J Brunner; Eleonor Fransson; Marcel Goldberg; Anders Knutsson; Markku Koskenvuo; Maria Nordin; Tuula Oksanen; Jaana Pentti; Reiner Rugulies; Martin J Shipley; Archana Singh-Manoux; Andrew Steptoe; Sakari B Suominen; Töres Theorell; Jussi Vahtera; Marianna Virtanen; Peter Westerholm; Hugo Westerlund; Marie Zins; Mark Hamer; Joshua A Bell; Adam G Tabak; Markus Jokela
Journal:  Lancet Public Health       Date:  2017-05-19

10.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.

Authors:  Laween Uthman; Antonius Baartscheer; Boris Bleijlevens; Cees A Schumacher; Jan W T Fiolet; Anneke Koeman; Milena Jancev; Markus W Hollmann; Nina C Weber; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2017-12-02       Impact factor: 10.122
View more
  1 in total

1.  Cardiologist as a cardiometabolic specialist.

Authors:  Vasiliki Katsi; Ioannis Andrikou; Costas Tsioufis; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-29       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.